All articles
How to Create a Wegovy® Diet Plan: A Step-by-Step Guide
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Clinical Findings on Wegovy
Studies highlight the effectiveness of Wegovy® in promoting weight loss and improving heart health. Participants using Wegovy® experienced significant reductions in waist circumference, systolic and diastolic blood pressure, and HbA1c levels, a marker for blood sugar. (5) Wegovy’s most commonly reported side effects include nausea, vomiting, diarrhea, and/or constipation. (1,2) These side effects are often worse upon starting the medication and resolve independently with time. Patients with a personal or family history of medullary thyroid cancer, those who have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and those who have had an allergic reaction to semaglutide in the past should not take this medication (1). Talk with your doctor to see if starting Wegovy® is right for you.
Key Takeaways for a Successful Wegovy® Diet Plan
Creating a Wegovy® diet plan involves careful planning and dedication. Following this guide, you can develop a balanced, nutritious meal plan supporting your weight loss goals while taking Wegovy®. Remember, the key to success is consistency, realistic goal-setting, and regular progress monitoring.
If you’re looking for more guidance on nutrition while using Wegovy® for weight loss, Mochi Health’s $79 monthly subscription offers visits with a provider and unlimited nutrition coaching with a registered dietitian. Start your journey towards a healthier you today and discover if you qualify for Mochi Health's comprehensive weight care program.
References:
Wegovy® (semaglutide) injection, for subcutaneous use. US Food and Drug Administration (FDA) approved product information. Revised July 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014 Mar 7;221(1):T1-16. doi: 10.1530/JOE-13-0414. PMID: 24323912. https://joe.bioscientifica.com/view/journals/joe/221/1/T1.xml#:~:text=2%20diabetes%20mellitus.-,GLP%2D1RA%20improve%20glycaemic%20control%20and%20stimulate%20satiety%2C%20leading%20to,of%20action%20have%20been%20proposed.
“Steps for Losing Weight.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/healthy-weight-growth/losing-weight/index.html#:~:text=A%20lifestyle%20with%20good%20nutrition,people%20who%20lose%20weight%20quickly.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















